- Home
- TBLD vs CTNM Comparison
TBLD vs CTNM Comparison
Compare TBLD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | TBLD | CTNM |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 700.3M | 575.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TBLD | CTNM |
|---|---|---|
| Price | $22.17 | $14.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | 73.8K | ★ 240.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.94 | $3.35 |
| 52 Week High | $22.23 | $16.01 |
Technical Indicators
Market Signals| Indicator | TBLD | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 81.15 | 61.95 |
| Support Level | $20.75 | $14.08 |
| Resistance Level | $22.05 | $15.39 |
| Average True Range (ATR) | 0.37 | 1.03 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 93.61 | 63.37 |
Price Performance
Historical ComparisonAbout TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.